Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL455119 | 0.82 | HTR2A (0.44) | DPP4HTR2AHTR2CTAAR1 | |
| SCHEMBL438764 | 0.82 | HTR2A (0.44) | DPP4HTR2AHTR2CTAAR1 | |
| SCHEMBL455108 | 0.79 | SLC6A2 (0.41) | DPP4HTR2AHTR2CTAAR1 | |
| SCHEMBL14071704 | 0.78 | DPP4 (0.70) | DPP4HTR2AHTR2CTAAR1 | |
| Hydrochloric Acid SCHEMBL3121618 | 0.77 | DPP4 (0.68) | DPP4HTR2AHTR2C | |
| SCHEMBL14478243 | 0.75 | DPP4 (0.41) | DPP4HTR2AHTR2CTAAR1 | |
| SCHEMBL14478251 | 0.74 | SLC6A2 (0.46) | HTR2AHTR2CTAAR1 | |
| SCHEMBL438633 | 0.74 | DPP4 (0.44) | DPP4HTR2AHTR2CTAAR1 | |
| SCHEMBL14478295 | 0.74 | SLC6A2 (0.46) | HTR2AHTR2CTAAR1 | |
| SCHEMBL439681 | 0.74 | DPP4 (0.44) | DPP4HTR2AHTR2CTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9273055-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2016-03-01 | — | — | US | disclosed |
| US-20150038536-A1 | TYROSINE KINASE INHIBITORS | CHEMBRIDGE COPRPORATION | 2015-02-05 | — | — | US | disclosed |
| US-8822500-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2014-09-02 | — | — | US | disclosed |
| WO-2012037155-A2 | TYROSINE KINASE INHIBITORS | GTX, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| US-20120065233-A1 | TYROSINE KINASE INHIBITORS | GREGOR VLAD EDWARD (US) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038536-A1 | TYROSINE KINASE INHIBITORS | ALK, ROS1, ABL1 | DPP4 2274/4885HTR2A 4642/4885HTR2C 4528/4885 |
| US-20120065233-A1 | TYROSINE KINASE INHIBITORS | ALK, ROS1, ABL1 | DPP4 2274/4885HTR2A 4642/4885HTR2C 4528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.